Accéder au contenu
Merck

Radiotherapy in poor risk patients with stage I cancer of the endometrium: results of not giving external beam radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain)) (1999-09-04)
B DeCruze, D Guthrie
RÉSUMÉ

Poor prognosis (poorly differentiated and/or deep myometrial invasion) Stage I endometrial cancer can have a relapse rate as high as 50%. Traditionally, most clinical oncologists treat these patients with external beam radiotherapy after surgery but there is no evidence to show that this improves survival. The retrospective study looks at the results of not giving external beam radiotherapy in 25 consecutive patients and compares the results with a group of 13 consecutive patients who did have such treatment. The two groups were comparable with regard to age, degree of differentiation and degree of invasion. Survival was comparable in the two groups. There is no evidence of any obvious decrease in survival from withholding external beam radiotherapy, but this was not a prospective randomized controlled trial. This study illustrates that it is essential that the Medical Research Council ASTEC trial should be supported because this will determine the true place of external beam radiotherapy in such patients.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Astec® Chirobiotic® R Chiral HPLC Column, 5 μm particle size, L × I.D. 15 cm × 4.6 mm
Supelco
Astec® Chirobiotic® R Chiral HPLC Column, 5 μm particle size, L × I.D. 25 cm × 4.6 mm
Supelco
Astec® Chirobiotic® R Chiral HPLC Column, 5 μm particle size, L × I.D. 15 cm × 2.1 mm
Supelco
Astec® Chirobiotic® R Chiral HPLC Column, 5 μm particle size, L × I.D. 10 cm × 4.6 mm
Supelco
Astec® Chirobiotic® R Chiral HPLC Column, 5 μm particle size, L × I.D. 25 cm × 2.1 mm